Head to Head Analysis: WuXi PharmaTech (Cayman) (NYSE:WX) versus The Competition

WuXi PharmaTech (Cayman) (NYSE: WX) is one of 189 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare WuXi PharmaTech (Cayman) to related companies based on the strength of its analyst recommendations, earnings, risk, institutional ownership, profitability, dividends and valuation.

Insider and Institutional Ownership

47.3% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 14.4% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares WuXi PharmaTech (Cayman) and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
WuXi PharmaTech (Cayman) N/A N/A 38.91
WuXi PharmaTech (Cayman) Competitors $217.40 million -$39.40 million -66.13

WuXi PharmaTech (Cayman)’s rivals have higher revenue, but lower earnings than WuXi PharmaTech (Cayman). WuXi PharmaTech (Cayman) is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for WuXi PharmaTech (Cayman) and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WuXi PharmaTech (Cayman) 0 0 0 0 N/A
WuXi PharmaTech (Cayman) Competitors 672 2546 6842 136 2.63

As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.77%. Given WuXi PharmaTech (Cayman)’s rivals higher probable upside, analysts clearly believe WuXi PharmaTech (Cayman) has less favorable growth aspects than its rivals.

Profitability

This table compares WuXi PharmaTech (Cayman) and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
WuXi PharmaTech (Cayman) 7.52% 6.93% 4.67%
WuXi PharmaTech (Cayman) Competitors -4,371.03% -466.68% -41.61%

About WuXi PharmaTech (Cayman)

WuXi PharmaTech (Cayman) Inc. is a pharmaceutical, biotechnology and medical device research and development (R&D) services company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers. It conducts its operations in two segments: Laboratory services and Manufacturing services. The Company offers Laboratory services for pharmaceutical, biotechnology and medical device companies. It offers Manufacturing services, which include the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients (APIs) for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologic products.

Receive News & Ratings for WuXi PharmaTech (Cayman) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi PharmaTech (Cayman) and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply